On June 1, Core Scientific rose 5.03% in regular trading, trading at $28.19 USD/share, with trading volume of approximately $108 million.
On the news front, B.Riley recently raised the company's target price from $30 to $33, maintaining a buy rating, with the average analyst target price at $30.12. The current stock price remains below consensus estimates, and the market continues to recognize further valuation recovery potential. Additionally, the company has recently filed multiple Form 4 and Schedule 13G/A documents, indicating ongoing changes in institutional investor positions. Market participants interpret this as a positive signal of capital inflows, collectively driving the stock higher after breaking through the previous key level of $24.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments